Low Dose Dasatinib Is Not As Active in a CML CP Cohort Enriched with Intermediate/High-Risk CML Chronic Phase: A Phase IIb Multi-Center Trial

Details

Language :

English

ISSN :

00064971 and 15280020

Volume :

140

Issue :

Supplement 1

Database :

Supplemental Index

Journal :

Blood

Publication Type :

Periodical

Accession number :

ejs61222155

Full Text :

https://doi.org/10.1182/blood-2022-169777